Maze Therapeutics

MAZE

Market cap $1.58B

Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease.

CNBC's Brian Sullivan sought to find the companies based in the city that were making investors the most money this year.

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D.

Investing in biotechnology stocks is complex due to the science behind the company's drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.

Maze Therapeutics, Inc. (NASDAQ:MAZE ) MZE782 Phase 1 Healthy Volunteer Trial Results Conference September 11, 2025 08:30 AM ET Company Participants Amy Bachrodt Jason Coloma - CEO & Director Harold Bernstein - President of Research & Development and Chief Medical Officer Misbah Tahir - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Tyler Van Buren - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Presentation Operator Good morning.

Maze Therapeutics, Inc. MAZE on Thursday shared clinical results from the Phase 1 healthy volunteer study of MZE782, an oral small molecule targeting the solute transporter, SLC6A19.

Maze Therapeutics catapulted Thursday after its experimental treatment for a rare, genetic disease blew past the company's own expectations.

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $150.0 million, before deducting placement agent fees and other expenses.

Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Misbah Tahir as chief financial officer (CFO), effective immediately.